Phasecraft team selected for Phase 2 of Wellcome Leap Quantum 4 Bio programme

We are delighted to announce that our team is one of just 8 worldwide proceeding to Phase 2 of the Wellcome Leap Quantum for Bio (Q4Bio) programme.

Together with University of Nottingham and QuEra Computing Inc we will take our work on  “Quantum computing for covalent inhibitors in drug discovery” to the next phase.

The Q4Bio programme aims to identify, develop and demonstrate biology and healthcare applications that will benefit from the quantum computers expected to emerge in the next 3-5 years.

The discovery of new drugs is currently one of the most challenging tasks facing medical innovation, and is consistently pushing the capabilities of current modelling tools to the limit. In this project, we will show how we can harness the combined power of quantum computing and classical simulation methods to tackle key biochemical questions with applications to drug discovery for myotonic dystrophy.

The Q4Bio programme started in 2023, when 12 teams were selected for its first phase, focusing on algorithms development. In the second phase, which is expected to be completed by Spring 2024, we will focus on large-scale simulations of the algorithms using classical high-performance computing.